OBJECTIVE: To evaluate naturalistic use of risperidone long-acting injection (RLAI) and its effect on healthcare resource use. METHOD: Mirror-image comparison of healthcare resource use for 3 years before RLAI initiation and 3 years after. RESULTS: In total, 211 of 277 patients consecutively prescribed RLAI were evaluable over the full 6-year study period. Median days in hospital/patient increased significantly in the 3 years after RLAI initiation [87 days (inter-quartile range 25-236) before vs. 192 days (47-426) after; P < 0.001]. Those 34 patients who continued RLAI for 3 years showed no change in median bed days [64 days (6.5-182) before vs. 64 days (12-180) after] and median number of admissions was decreased [1.5 (1-2.25) before vs. 1.00 (0-1.25) after; P = 0.001]. Healthcare costs more than doubled for the whole cohort (P < 0.001) and discontinuers (P < 0.001) and increased significantly for continuers (P = 0.010). CONCLUSION: RLAI did not decrease either time spent in hospital or overall healthcare costs in this patient cohort.
OBJECTIVE: To evaluate naturalistic use of risperidone long-acting injection (RLAI) and its effect on healthcare resource use. METHOD: Mirror-image comparison of healthcare resource use for 3 years before RLAI initiation and 3 years after. RESULTS: In total, 211 of 277 patients consecutively prescribed RLAI were evaluable over the full 6-year study period. Median days in hospital/patient increased significantly in the 3 years after RLAI initiation [87 days (inter-quartile range 25-236) before vs. 192 days (47-426) after; P < 0.001]. Those 34 patients who continued RLAI for 3 years showed no change in median bed days [64 days (6.5-182) before vs. 64 days (12-180) after] and median number of admissions was decreased [1.5 (1-2.25) before vs. 1.00 (0-1.25) after; P = 0.001]. Healthcare costs more than doubled for the whole cohort (P < 0.001) and discontinuers (P < 0.001) and increased significantly for continuers (P = 0.010). CONCLUSION: RLAI did not decrease either time spent in hospital or overall healthcare costs in this patient cohort.
Authors: Richard Hayes; Robert Stewart; Giouliana Kadra-Scalzo; Deborah Ahn; Alex Bird; Matthew Broadbent; Chin-Kuo Chang; Megan Pritchard; Hitesh Shetty; David Taylor Journal: BMJ Open Date: 2022-04-06 Impact factor: 2.692